{
    "symbol": "RDY",
    "quarter": 3,
    "year": 2023,
    "date": "2023-01-25 14:26:14",
    "content": " One, strong revenue growth driven by continued traction US and Russia markets; second, high cash generation leading to net cash surplus of more than $400 million at the end of the quarter. Our PSAI business recorded sales of 95 million with the innovative decline of 2%, however strong growth of 18% on sequential quarter basis, contribute by an improvement of the volume pick up. Thank you very much. Thank you very much. Thank you very much. Just on the REVLIMID side, if you could say something more on the kind of visibility in terms of -- like -- it seems that first two quarters -- or in the last two quarters, whatever number that we would have generated, it seems that we have already achieved around 5% odd mid-single-digit kind of volume set in the product opportunity. Because, what I have seen that you have already indicated that and you are likely to be -- or you're likely to remain active in terms of inorganic growth as well as the R&D spend also, rate, if I see, it has just moved on, along with the kind of ramp up in the revenues. Thank you very much."
}